Biora Therapeutics, Inc.
BIORQ Healthcare Biotechnology
Operating cash flow growth for three consecutive years.
Follow BIORQ
Biora Therapeutics, Inc. (BIORQ) EV/Sales
As of 15 October 2026, Biora Therapeutics, Inc. (BIORQ) trades at a EV/Sales of 67.4×. Over the past ten years it has ranged from −0.6× (August 2020) to 4,719× (October 2023); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 525× | 37.93% |
| FY2022 | 381× | 23.32% |
| FY2021 | 309× | 3,105.97% |
| FY2020 | 9.6× | 762.07% |
| FY2019 | 1.1× | 0.00% |
| FY2018 | 1.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 273× | 274.65% |
| Jun 2024 | 72.7× | (27.21%) |
| Mar 2024 | 99.9× | (93.46%) |
| Jun 2023 | 1,527× | 136.79% |
| 16 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELAB PMGC Holdings Inc. compare | −6.7× |
| GOVX GeoVax Labs Inc. compare | −0.3× |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | 0.0× |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | 4.4× |
| VBIO Valion Bio, Inc. compare | 11.3× |
| NTBLQ Notable Labs, Ltd. compare | 23.3× |
| BIORQ Biora Therapeutics, Inc. | 67.4× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)